CELLSEARCH® CTC count proves its clinical utility in guiding therapeutic strategy supporting patient care in HR+/HER2- metastatic breast cancer

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

MSB-Trial-Data

More Like This

PR Newswire associated0

Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH® CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype

PR Newswire associated0

Menarini Silicon Biosystems announces publication of the DETECT III trial results highlighting the potential clinical utility of HER2 testing in circulating tumor cells with CELLSEARCH

PR Newswire associated0

Menarini Silicon Biosystems announces new study results on use of CELLSEARCH® liquid biopsy for earlier detection of relapse and to help inform decisions on patient management in stage III Melanoma

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients

AACR 2026: First‑in‑Human STC‑1010 Data Show Favorable Safety and Early Immune Engagement in Metastatic MSS Colorectal Cancer

New Novotech Report on Metastatic Breast Cancer Identifies 1,000 Clinical Trials Globally Since 2018

The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the platform features three complexity levels: standard (cancer cells), intermediate (+fibroblasts), and advanced (+immune/endothelial cells) . A key breakthrough is its record cellular viability of 128 days, enabling unprecedented long-term studies on drug resistance and metastasis . Ultimately, CTIONCOTEST delivers a highly predictive, 100% human-derived ethical alternative to animal testing.

Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care

Brenus Pharma Announces First Patients Dosed in its First-in-Human Trial Evaluating STC-1010, a Next-Generation Immunotherapy